Biogen’s new potential treatment for Alzheimer’s disease could be the biggest drug ever and cause an earthquake in the drug market. The company added $ 17 billion to its market value this week when the Food and Drug Administration hinted in published documents that regulators are convinced the drug works.
The best indication came this morning (Friday) when the FDA Advisory Committee decided to recommend a drug approval and thus actually gave the green light that could raise Biogen more, but may be much more worthwhile to the drug industry in general.
It’s easy to imagine the company led by Michelle Venatus reaping huge revenues – Alzheimer’s is particularly common and destructive, with no effective treatments to date. Market analyzes have shown that a third of the 2.2 million Americans with mild dementia will be able to receive the new drug within three years. Assuming a price of $ 50,000 a year, this is an annual revenue of $ 40 billion. However, in the opinion of banks global use worldwide will probably be lower.
Biogen’s market capitalization before the news on Wednesday was $ 38 billion, but the stock jumped more than 40 percent. Biogen’s new treatment. The company conducted two essentially large studies that were essentially the same, with one showing apparent efficacy and the other failing. Usually, this is not enough. Furthermore, other similar potential drugs have a history of bombing in clinical trials.
However, the FDA seems to think that Biogen’s successful study was convincing. Shareholders in companies like Biogen were happy. But selling expensive new drugs with marginal benefits at best will not help many patients – or curb spending in the US.
Comments on the article(0):
Your response has been received and will be published subject to system policies.
Thanks.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment
These were the details of the news The drug for Alzheimer’s kills Biogen for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at news1.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
